Yahoo Finance • 4 days ago

Personalis falls amid a downgrade as a competitive bid appears unlikely

[Blood test sample for Tumor markers test for diagnosis cancer] angelp Personalis Inc. (PSNL [https://seekingalpha.com/symbol/PSNL]) dropped 6% amid a downgrade at Craig-Hallum to hold from buy as the cancer test maker is unlikely to see... Full story

Yahoo Finance • 24 days ago

PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI

MONSEY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Personalis, Inc. (Nasdaq: PSNL) (“Personalis”) to Tempus AI, Inc. (“Tempus”) for $16.25 per... Full story

Yahoo Finance • 30 days ago

Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • last month

Halper Sadeh LLC is Investigating Whether LXP, FNWD, PSNL are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • last month

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)

BALA CYNWYD, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • last month

Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion

Tempus AI announced Monday it has entered into a definitive agreement to acquire Personalis, a cancer-monitoring company, in a deal valued at $1.5 billion. Personalis shareholders will receive $16.25 per share, representing a 6% premium to... Full story

Yahoo Finance • last month

Cathie Wood Dumps $39 Million Worth of AMD Stock

This article first appeared on GuruFocus. Cathie Wood's ARK Invest reduced its position in Advanced Micro Devices (NASDAQ:AMD) during the week ended July 17, making the chipmaker its largest sale of the period. ARK sold approximately $39... Full story

Yahoo Finance • last month

Tempus AI Bets on MRD Testing Growth With Personalis Acquisition

MarketBeat Week in Review – 02/23 - 02/27 Tempus AI (NASDAQ:TEM) executives said the company's planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biop... Full story

Yahoo Finance • last month

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing... Full story

Yahoo Finance • last month

Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded. Continue Reading... Full story

Yahoo Finance • last month

Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B

Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B Proactive uses images sourced from Shutterstock Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in t... Full story

Yahoo Finance • 2 months ago

Cathie Wood reshuffles portfolio ahead of Q2, buys SpaceX, Eli Lilly, Meta; pares AMD, Roku

Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52... Full story

Yahoo Finance • 3 months ago

Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?

Christopher M. Hall, Chief Executive Officer of Personalis(NASDAQ:PSNL), disclosed the direct exercise and immediate sale of 100,000 shares of Common Stock, valued at approximately $1.10 million, in a transaction reported on May 29, 2026.... Full story

Yahoo Finance • 3 months ago

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Quantum Cyber (NASDAQ:QUCY) shares increased by 55.0% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 21.26%... Full story

Yahoo Finance • 6 months ago

Lightspeed Management Made a Huge Bet on Navan (NAVN) With a Purchase of 49.9 Million Shares

What happened According to an SEC filing dated February 17, 2026, Lightspeed Management Company, L.L.C. initiated a new position in Navan(NASDAQ:NAVN), acquiring 49,921,454 shares. The quarter-end value of the NAVN position stood at $852.... Full story

Yahoo Finance • 7 months ago

AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares

On February 2, 2026, AIGH Capital Management LLC fully exited its stake in MaxLinear(NASDAQ:MXL), selling 1,107,504 shares in a transaction estimated at $17.81 million based on quarterly average pricing. What happened According to a Secu... Full story

Yahoo Finance • 8 months ago

Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL)

Personalis, Inc. (NASDAQ:PSNL) is among the 12 Best Genomics Stocks to Invest In.Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) The Fly reported on December 2, 2025, that Morgan Stanley analyst Kallum Titc... Full story

Yahoo Finance • 10 months ago

Personalis narrows 2025 revenue outlook to $68M-$73M amid biopharma project delays and rapid clinical test growth

Earnings Call Insights: Personalis, Inc. (PSNL) Q3 2025 MANAGEMENT VIEW * CEO Christopher Hall highlighted, "Q3 was another step forward in our Win-in-MRD strategy. We delivered 4,388 clinical tests, a 26% sequential and 364% year-over... Full story

Yahoo Finance • 10 months ago

Dexcom Appoints Euan Ashley to Board of Directors

SAN DIEGO, October 27, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renow... Full story